08:00 , Feb 4, 2013 |  BioCentury  |  Emerging Company Profile

Incanthera: Using, not targeting, MMP

Incanthera Ltd. has found a new use for a class of enzymes that are up-regulated in tumors and contribute to cancer progression. Rather than design inhibitors of matrix metalloproteinases , the biotech is instead using...
07:00 , Jul 2, 2012 |  BC Week In Review  |  Company News

Angiogene Pharmaceuticals, OxiGene deal

Angiogene granted OxiGene exclusive, worldwide rights to IP, patents and preclinical data related to Angiogene's vascular disrupting agent to treat carcinoid syndrome. OxiGene plans to use the IP to develop its Zybrestat fosbretabulin to treat...
07:00 , Jun 19, 2006 |  BioCentury  |  Product Development

More is less in CNS

Running clinical trials can be complicated when some of the disease symptoms a compound is designed to treat are also side effects of the compound. MediciNova Inc. ran into just such a conundrum with its...